University of Wollongong
Browse

A multi-centre randomized, open-label phase II trial of erlotinib plus gemcitabine or gemcitabine monotherapy as first-line therapy in ECOG PS2 patients with chemo-naive advanced NSCLC

Download (159.33 kB)
journal contribution
posted on 2024-11-14, 00:31 authored by Michael Michael, Michael Johnston, Stephen Clarke, Richard de Boer, Phillip ClinganPhillip Clingan, Nick Pavlakis
The abstract for this item has not been populated

History

Citation

Michael, M., Pavlakis, N., Clingan, P., De Boer, R., Johnston, M., & Clarke, S. (2009). A multi-centre randomized, open-label phase II trial of erlotinib plus gemcitabine or gemcitabine monotherapy as first-line therapy in ECOG PS2 patients with chemo-naive advanced NSCLC. In 13th World Conference on Lung Cancer Vol. 4 (pp. S699). San Francisco: Lippincott Williams & Wilkins, USA.

Volume

4

Issue

9

Pagination

S699-S699

Language

English

RIS ID

31631

Usage metrics

    Categories

    Keywords

    randomizedcentremultinaivechemopatientsps2ecogtherapylinefirstmonotherapygemcitabinepluserlotinibtrialnsclciiadvancedphaselabelopen

    Licence

    Copyright - All rights reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC